Cellceutix Corporation

March 10, 2017

Cellceutix Reports Positive Interim Results from Brilacidin Phase 2 Clinical Trial

News

Positive interim results were reported in the first two groups of ulcerative colitis patients being treated with Brilacidin (PMX-30063) in a dose-escalating Phase 2 clinical trial. Patients for a third and final group — ... Read more

January 18, 2017

Cellceutix Enrolls Second Group in Phase 2 Trial of IBD Therapy Brilacidin

News

Cellceutix has completed enrolling a second cohort of patients with mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS), two forms of inflammatory bowel disease (IBD), in its Phase 2 clinical trial evaluating brilacidin (PMX-30063). ... Read more

June 21, 2016June 21, 2016

Cellceutix Begins Phase 2 Trial of Ulcerative Proctitis Drug Candidate Brilacidin

Crohn's Disease, IBD News, News, Ulcerative colitis

Cellceutix recently began screening participants and administering therapy for its Phase 2 trial assessing the drug candidate Brilacidin for the treatment of ulcerative proctitis, a mild form of ulcerative colitis. The causes for ... Read more

January 27, 2015January 27, 2015

Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy

News

Clinical stage biopharmaceutical company, Cellceutix Corporation, is submitting a request to the U.S. Food and Drug Administration (FDA) for a pre-Investigational New Drug (IND) meeting. The company, which is dedicated to developing novel treatments with oncology, ... Read more